

Elimination of Viral Hepatitis in the Czech Republic, Hungary, Poland and Slovakia: Lessons Learnt and the Way Forward

> PRAGUE, CZECH REPUBLI 29-30 October 2024

An overview of the hepatitis epidemiological status in Czech Republic, Hungary, Poland and Slovakia

Danica Valkovičová Staneková

St. Elizabeth University of Health & Social work
Bratislava, Slovakia


stanekova@vssvalybet.sk

Hepatitis B

Annual Epidemiological Report for 2022



Figure 2. Notification rate of hepatitis C cases per 100 000 population by country*, EU/EEA, 2022



For 2022, 30 EU/EEA countries reported 28 855 cases of HBV infection, which coresponds to a crude rate of 8.5 cases per 100 000 population.

Hepatitis B

Annual Epidemiological Report for 2022




Table 2. Number of reported hepatitis B cases and rates per 100 000 population by country and year, 2018–2022

Country	2018		2019		2020 2021 2022											
	Alla		Alla		Alla		Alla		All		Acute		Chronic		Unkno	wn
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Czechia	323	3.0	317	3.0	169	1.6	144	1.3	266	2.5	48	0.46	218	2.07	NDR	NRC
Hungary	NDR	NRC	NDR	NRC	NDR	NRC	NDR	NRC	NDR	NRC	23	0.2	NDR	NRC	NDR	NRC
Poland	3 196	8.4	2 854	7.5	992	2.6	1 547	4.1	2 500	6.6	29	0.1	0	0.0	2 471	6.6
Slovakia	131	2.4	141	2.6	89	1.6	77	1.4	98	1.8	98	1.8	0	0.0	NDR	NRC
Total EU/EEA (30 countries)	16 606	4.8	20 581	6.1	14 332	4.2	15 830	4.7	28 420	8.5	1 971	0.5	11 388	4.6	13 674	5.2

24 EU countries were able to provide data on acute cases.


The overall notification rate of acute cases was 0.5 cases per 100 000 population, ranging from 0 cases in Iceland and Malta to 1.8 cases per 100 000 population in Finland and Slovakia

HBV acute cases




http://atlas.ecdc.europa.eu/public/index.aspx

HBV acute cases



'Nosocomial transmission' includes transmissions that occurred in hospitals, nursing homes, psychiatric institutions and dental services. This category refers mainly to patients exposed through healthcare settings, distinct from 'needle-stick and other occupational exposure', which refers to staff.


HBV acute cases under age 25 year






http://atlas.ecdc.europa.eu/public/index.aspx

HBV acute cases under age 25 year





Hepatitis B

Annual Epidemiological Report for 2022




Table 2. Number of reported hepatitis B cases and rates per 100 000 population by country and year, 2018–2022

Country	2018		2019		2020 2021 2022											
	Alla		Alla		Alla		Alla		All		Acute		Chronic		Unkno	wn
	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate	Number	Rate
Czechia	323	3.0	317	3.0	169	1.6	144	1.3	266	2.5	48	0.46	218	2.07	NDR	NRC
Hungary	NDR	NRC	NDR	NRC	NDR	NRC	NDR	NRC	NDR	NRC	23	0.2	NDR	NRC	NDR	NRC
Poland	3 196	8.4	2 854	7.5	992	2.6	1 547	4.1	2 500	6.6	29	0.1	0	0.0	2 471	6.6
Slovakia	131	2.4	141	2.6	89	1.6	77	1.4	98	1.8	98	1.8	0	0.0	NDR	NRC
Total EU/EEA (30 countries)	16 606	4.8	20 581	6.1	14 332	4.2	15 830	4.7	28 420	8.5	1 971	0.5	11 388	4.6	13 674	5.2

24 EU countries were able to provide data on chronic cases.


The overall notification rate of chronic cases was 4.6 cases per 100 000 population, ranging from 0 cases in Luxembourg, Poland and Slovakia to 13.8 cases per 100 000 population in Iceland


HBV chronic cases



http://atlas.ecdc.europa.eu/public/index.aspx

HBV incidence – distribution by age in SR /2018 – 2022/






1st case: not vaccinated child born to HBsAg positive mothers living in low hygiene standard family

2nd case: 12 years child born HBsAg positive mother, after delivery vaccinated with 3 doses of Engerix, IgG prophylaxis unknown, The child lives in a family with low hygiene standards /vaccine failure/.

https://www.uvzsr.sk/web/uvz/vyrocne-spravy




One case of the disease was recorded in a 10-year-old child from an environment with low hygienic standard ,properly vaccinated with 3 doses of hexavaccine /vaccine failure/.

https://www.uvzsr.sk/web/uvz/vyrocne-spravy

(B16) Výskyt vírusovej hepatitídy typu B / Incidence of viral hepatitis B.

Vekovošpecifická chorobnosť.

Rok 2023, mesiac január až december. SR.



1 case: child properly vaccinated with 3 doses, tatooed in incubation time before the disease. The child lives in an environment with low hygienic and social conditions.


https://www.uvzsr.sk/web/uvz/vyrocne-spravy

Prevention of hepatitis B and C in the EU/EEA

April 2024



Figure 6. Coverage of antenatal screening for HBV in EU/EEA countries with available data, 2022 (or most recent year with data)



Prevention of hepatitis B and C in the EU/EEA

ELROPIAN CENTRE FOR NATIO CONTRO.


April 2024

Table 2. Estimated proportion of pregnant women screened for HBsAg infection in 2022 (or most recent year with data) who tested positive, in the EU/EEA

Country	Estimated proportion of pregnant women screened for HBsAg infection who tested positive
Czechia	0.25%
Denmark	0.17%
Estonia	<0.1%
France	0.84%
Hungary	0.08%
Ireland	0.51%
Italy	0.86%
Netherlands	0.22%
Poland	0.87%
Slovakia	0.07%

Source: ECDC hepatitis monitoring survey, 2023

Figure 4. Coverage (%) of three doses of hepatitis B vaccine (HB3) in EU/EEA countries that implement universal HBV vaccination, 2022



^{*} Country did not provide data.

NB. Denmark, Finland and Iceland do not have a national policy for universal childhood vaccination against hepatitis B and Hungary has a universal vaccination programme targeting school-aged children.

Source: WHO/UNICEF coverage estimates [16]

SURVEILLANCE REPORT

Hepatitis C

EUROPEAN CENT DISEASE PREVENT AND CONTROL


Annual Epidemiological Report for 2022

Hepatitis C cases and rates per 100 000 population by country and year, EU/EEA, 2018-2022

	2018		2019		2020		2021		2022								
Country	All ^I		All ¹		All ¹		All ¹		All		Acute		Chronic		Unknown		
	Cases	Rate	Cases	Rate	Cases	Rate	Cases	Rate	Cases	Rate	Cases	Rate	Cases	Rate	Cases	Rate	
Czechia	1 050	9.9	1 138	10.7	771	7.2	762	7.3	820	7.8	93	0.9	727	6.9	NDR	NRC	
Hungary	NDR	NRC	NDR	NRC	NDR	NRC	NDR	NRC	NDR	NRC	24	0.2	NDR	NRC	NDR	NRC	
Poland	3 442	9.1	3 343	8.8	955	2.5	1 244	3.3	2 528	6.7	9	0.0	0	0.0	2 519	6.7	
Slovakia	225	4.1	247	4.5	204	3.7	183	3.4	322	5.9	13	0.2	309	5.7	NDR	NRC	
EU/EEA (30 countries)	21 753	5.9	21 632	5.7	14 662	4.0	15 224	4.3	23 249	6.2	1 308	0.4	7 842	2.9	13 377	4.1	


In 2022, 23 273 cases of HCV were reported in 29 EU/EEA countries, corresponding to a crude rate of 6.2 cases per 100 000 population. Of the cases reported, 6% were acute, 34% chronic, and 57% were unknown.


HCV acute cases




http://atlas.ecdc.europa.eu/public/index.aspx

HCV acute cases in 2022






HCV acute cases - age below 25




http://atlas.ecdc.europa.eu/public/index.aspx

HCV acute cases- age below 25 in 2022




HCV chronic cases






http://atlas.ecdc.europa.eu/public/index.aspx

HCV chronic cases




HCV incidence - age-specific morbidity in SR /2018 - 2023/



(B17.1) Výskyt vírusovej hepatitídy typu C / Incidence of viral hepatitis C.

Vekovošpecifická chorobnosť.



- 1. case: a newborn HCV was detected in within screening examinations. history of the mother tattoos, long-term drug use, homeless, nicotinism, not tested for HCV, nevertheless assumed vertical transmission
- 2. case: 2 years old child living in an environment with low hygienic standard, mother anti HCV negative, aunt HCV positive with a tattoo history. Probable transmission of the infection through the use of common hygiene items.
- https://www.uvzsr.sk/web/uvz/vyrocne-spravy

Prevention of hepatitis B and C in the EU/EEA



April 2024

Conclusion

The decline in the reported number of new transmissions of HBV and HCV infections across European Union and European Economic Area countries has continued, but the burden remains high, with an estimated 5.4 million people with chronic HBV and HCV infection in the region in 2022.

Therefore, there is a need to scale up interventions to improve testing, linkage to care and initiation of treatment for HBV/HCV infection.

Thank you for your attention!

